Cancer Biologics Market

Cancer Biologics Market (Drug Class: Monoclonal Antibodies (mAb), Recombinant Proteins, Cancer Growth Inhibitors, Vaccines, CAR-T Cells, Angiogenesis Inhibitors, Interleukins (IL), and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Cancer Biologics Market Outlook 2031

  • The global industry was valued at US$ 94.5 Bn in 2022
  • It is projected to grow at a CAGR of 7.7% from 2023 to 2031 and reach more than US$ 185.0 Bn by the end of 2031

Analysts’ Viewpoint

Rise in prevalence of cancer, advancements in cancer biotechnology, increase in demand for targeted therapies, and favorable reimbursement policies are the major factors driving the global cancer biologics market. Cancer continues to be a significant health challenge globally, with 10 million fatalities in 2020. Surge in need for effective and innovative treatments of cancer is propelling the cancer biologics market growth. Furthermore, advancements in understanding cancer biology, identifying specific molecular targets, and developing biologic drugs that can selectively target and inhibit cancer cells are expected to accelerate market expansion.

Rise in demand for targeted therapies, as these offer improved treatment outcomes and reduced side effects compared to traditional chemotherapy, offers lucrative opportunities to market players. Moreover, favorable reimbursement policies by governments and insurance providers have encouraged the adoption of cancer biologics, ensuring wider patient access to these advanced treatments.

Cancer Biologics Market

Global Cancer Biologics Market Introduction

The cancer biologics market encompasses a range of therapeutic products developed through biotechnology to treat various types of cancer. Biologic drugs are derived from living organisms, such as cells or proteins, and are designed to target specific cancer cells or pathways.

These drugs include monoclonal antibodies, vaccines, and cell-based therapies. These work by enhancing immune response, blocking tumor growth signals, or directly attacking cancer cells.

The market has witnessed significant developments in the past few years, including approval of novel biologic therapies, expansion of targeted therapies, and advancements in immunotherapies.

Targeted therapies, such as HER2-targeted antibodies for breast cancer or EGFR inhibitors for lung cancer, have shown improved treatment outcomes. Immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies have demonstrated remarkable success in certain cancers.

The market continues to evolve with ongoing research and development efforts to discover new therapeutic targets and optimize treatment approaches, aiming to provide more effective and personalized options for cancer patients.

Increase in Incidence of Cancer

Rise in number of cancer cases across the globe has increased the need for effective and targeted therapies to combat this complex disease.

Surge in cancer incidence can be attributed to several factors. Population growth, aging population, and lifestyle changes have contributed to the increasing burden of cancer. Additionally, improved diagnostic techniques and increased awareness have led to better detection and reporting of cancer cases.

Rise in cancer cases has spurred significant advancements in the field of cancer treatment, with a particular focus on biologic drugs. Biologics, derived from living organisms or produced using biotechnology, offer unique advantages over traditional chemotherapy drugs.

Biologics can target specific molecules or pathways involved in cancer growth and progression, leading to more precise and personalized treatment approaches. Increase in cancer incidence has prompted greater research and development efforts in the field of oncology biologics.

Pharmaceutical companies, academic institutions, and research organizations are investing significantly in developing novel biologic drugs and conducting clinical trials to evaluate their safety and efficacy. The focus is not only on improving existing treatments, but also on discovering innovative approaches to combatting cancer.

Advancements in Biotechnology

Advancements in biotechnology are playing a crucial role in driving the global cancer biologics market demand. Biotechnology has revolutionized the field of cancer research and treatment by enabling the development of innovative biologic drugs with enhanced specificity, efficacy, and safety profiles.

One of the key advancements in biotechnology is the ability to produce monoclonal antibodies (mAbs). These biologic drugs are engineered to target specific molecules or proteins expressed on the surface of cancer cells.

By binding to these targets, mAbs can block signaling pathways, inhibit tumor growth, and stimulate immune responses against cancer cells. Development of techniques such as hybridoma technology and recombinant DNA technology has facilitated large-scale production of mAbs with high precision and consistency.

Advent of recombinant DNA technology and genetic engineering has enabled the creation of novel biologic drugs for cancer treatment. This technology enables the manipulation and modification of genes to produce therapeutic proteins with desired characteristics. For instance, the production of erythropoietin (EPO) using recombinant DNA technology has revolutionized the treatment of anemia associated with cancer and chemotherapy.

Development of targeted therapies is another breakthrough in biotechnology that is driving global cancer biologics market value. These therapies focus on specific molecular targets that play a critical role in cancer growth and progression. These are designed to inhibit the activity of these targets and disrupt the signaling pathways involved in tumor development.

Targeted therapies can be small molecules or biologic drugs, such as tyrosine kinase inhibitors or proteasome inhibitors, which selectively target cancer cells while sparing healthy cells.

Biotechnology has facilitated significant advancements in cancer immunotherapies. Immune checkpoint inhibitors, a form of immunotherapy, block inhibitory signals that cancer cells use to evade the immune system's attack.

This approach has shown remarkable success in treating various types of cancer, including melanoma, lung cancer, and bladder cancer. Biotechnology has enabled the production of these biologic drugs that can restore and enhance the body's immune response against cancer cells.

Ability to Specifically Target Cancer Cells Bolstering Monoclonal Antibodies Segment

In terms of drug class, the monoclonal antibodies (mAbs) segment accounted for the largest global cancer biologics market share in 2022. This is ascribed to their unique properties and therapeutic potential.

One of the key reasons for their prominence is the ability to specifically target cancer cells or tumor-associated antigens, while sparing healthy cells. This targeted approach minimizes off-target effects and reduces the risk of systemic toxicity, making mAbs an attractive treatment option.

Monoclonal antibodies continue to be actively researched and developed for novel targets and therapeutic approaches. Emergence of bispecific antibodies, capable of simultaneously binding to two different targets, has gained attention in the past few years. These antibodies can be engineered to engage both cancer cells and immune cells, facilitating the destruction of cancer cells through immune-mediated mechanisms. Bispecific antibodies, such as blinatumomab (Blincyto) for acute lymphoblastic leukemia, represent a promising advancement in cancer treatment.

Advancements in antibody engineering and optimization techniques have enabled the development of next-generation monoclonal antibodies with improved efficacy and reduced immunogenicity. Antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP) properties have shown increased tumor-killing capabilities.

Biologic Drugs Specifically Target Underlying Mechanisms of Blood Cancer

Based on application, the blood cancer segment dominated the global cancer biologics industry in 2022. The segment includes leukemia, lymphoma, and multiple myeloma. Blood cancers are a diverse group of malignancies with distinct molecular and genetic characteristics, making them amenable to targeted therapies.

This has led to the development of numerous biologic drugs that specifically target the underlying mechanisms driving blood cancer growth and proliferation. Prevalence of blood cancer is high globally, and a wide range of biologics are available for treatment.

Ongoing research & development efforts in the field of blood cancer biologics continue to expand treatment options. Clinical trials are exploring novel monoclonal antibodies, antibody-drug conjugates, CAR-T cell therapies, and other biologic approaches to further enhance the effectiveness of treatment.

Ability to Provide Comprehensive Care Fueling Hospitals Segment

In terms of end-user, the hospitals segment accounted for the largest market share in 2022. Hospitals have a multidisciplinary approach to cancer care. These settings have a team of healthcare professionals, including medical oncologists, hematologists, radiation oncologists, and specialized nurses, who collaborate to develop comprehensive treatment plans for cancer patients.

This multidisciplinary approach facilitates the integration of cancer biologics into the overall treatment strategy, ensuring proper patient selection, monitoring, and management.

Hospitals often have established partnerships and collaborations with pharmaceutical companies and research institutions. These collaborations enable hospitals to participate in clinical trials and access the latest advancements in cancer biologics. Therefore, they have the advantage of early adoption and integration of new biologic therapies into their treatment protocols.

The ability to provide comprehensive care is another factor driving the hospitals segment. Cancer treatment often involves a combination of therapies, including surgery, radiation therapy, chemotherapy, and biologic therapies. Hospitals can offer all these treatment modalities under one roof, ensuring seamless coordination and continuity of care for patients.

Regional Outlook

As per cancer biologics market trends, North America emerged as a major market for cancer biologics in 2022. This is ascribed to advanced healthcare infrastructure, strong research & development capabilities, favorable regulatory environment, and high healthcare expenditure in the region.

North America is also home to prominent pharmaceutical companies and biotechnology firms that are at the forefront of cancer research and innovation. These companies have the expertise and resources to invest in the development of biologic drugs and conduct clinical trials to evaluate their safety and efficacy.

The region's strong research & development capabilities contribute to the continuous pipeline of new and improved cancer biologics.

Asia Pacific has witnessed steady rise in cancer cases, attributed to factors such as population growth, aging population, and lifestyle changes. This surge in cancer incidence has increased demand for effective cancer treatments, including biologic drugs.

Improving healthcare infrastructure is another crucial factor driving the cancer biologics market size in Asia Pacific. Countries in the region have been investing significantly in healthcare infrastructure, including the establishment of advanced hospitals, cancer centers, and research institutes. This improved infrastructure enables the development, production, and distribution of biologic drugs for cancer treatment, enhancing patient access to these therapies.

Analysis of Key Players

The global cancer biologics market is fragmented, with the presence of large number of players. Companies in the market have adopted strategies such as investment in R&D, product portfolio expansion, and merger & acquisition in order to increase market share and presence.

F. Hoffmann-La Roche Ltd., Amgen, Inc., Pfizer, Inc., GSK plc., Bristol-Myers Squibb Company, Abbott, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Inc., and Johnson & Johnson Services, Inc.

Key Developments in Global Cancer Biologics Market

  • In March 2022, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) regarding the Biologics License Application (BLA) for sintilimab injection, an investigational medicine. Sintilimab is a PD-1 inhibitor intended for use in combination with pemetrexed and platinum chemotherapy as a first-line treatment for individuals diagnosed with nonsquamous non-small cell lung cancer (NSCLC).
  • On May 19, 2023, AbbVie announced the approval of EPKINLYTM (epcoritamab-bysp) by the U.S. Food and Drug Administration (FDA). This marks a significant milestone as EPKINLYTM becomes the first and only T-cell engaging bispecific antibody approved for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBL), who have undergone two or more lines of systemic therapies.

The cancer biologics market report profiles top players based on various factors including a company overview, financial summary, strategies, product portfolio, segments, and recent advancements.

Global Cancer Biologics Market Snapshot

Attribute Detail

Size in 2022

US$ 94.5 Bn

Forecast Value in 2031

More than US$ 185.0 Bn

CAGR - 2023-2031

7.7 %

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Drug Class
    • Monoclonal Antibodies (mAb)- major share
      • Naked mAb
      • Conjugated mAb
      • Bispecific mAb
    • Recombinants Proteins
    • Cancer Growth Inhibitors
      • Tyrosine Kinase Inhibitors
      • mTOR Inhibitors
      • Others (proteasome inhibitors)
    • Vaccines
      • Preventive Vaccines
      • Therapeutic Vaccines
    • CAR-T Cells
    • Angiogenesis Inhibitors
    • Interleukins (IL)
    • Others (interferons (IFN), gene therapy, etc.)
  • Application
    • Blood Cancer
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Gastric Cancer
    • Ovarian Cancer
    • Others (skin, liver cancer, etc.)
  • End-user
    • Hospitals
    • Cancer Centers
    • Academics & Research Institutes

Regions Covered

  • Asia Pacific
  • Latin America
  • Middle East & Africa
  • Rest of the World

Countries Covered

  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • F. Hoffmann-La Roche Ltd.
  • Amgen, Inc.
  • Pfizer, Inc.
  • GSK plc.
  • Bristol-Myers Squibb Company
  • Abbott
  • AstraZeneca
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global cancer biologics market in 2022?

The global industry was valued at US$ 94.5 Bn in 2022

How big will be the cancer biologics industry in 2031?

It is projected to reach US$ 185.0 Bn by 2031

What will be the CAGR of the cancer biologics business during the forecast period?

The industry is anticipated to expand at a 7.7% from 2023 to 2031

Which drug class segment held leading market share of the cancer biologics?

The monoclonal antibody (mAb) segment held the leading share in 2022

Which region will account for major market share of the cancer biologics during the forecast period?

North America is expected to account for largest share from 2022 to 2031

Who are the prominent cancer biologics players?

F. Hoffmann-La Roche Ltd., Amgen, Inc., Pfizer, Inc., GSK plc, Bristol-Myers Squibb Company, Abbott, AstraZeneca, Eli Lilly and Company, Gilead Sciences, Inc., and Johnson & Johnson Services, Inc. are the prominent players in the market.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Biologics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Cancer Biologics Market Analysis and Forecast, 2017-2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Overview: Advances in Cancer Diagnostics & Therapeutics

    5.3. Cancer Incidence & Prevalence Rate by Region/Key Countries

    5.4. Key Product Brand Analysis

    5.5. Covid-19 Impact Analysis

6. Global Cancer Biologics Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017-2031

        6.3.1. Monoclonal Antibodies (mAb)

            6.3.1.1. Naked mAb

            6.3.1.2. Conjugated mAb

            6.3.1.3. Bispecific mAb

        6.3.2. Recombinants Proteins

        6.3.3. Cancer Growth Inhibitors

            6.3.3.1. Tyrosine Kinase Inhibitors

            6.3.3.2. mTOR Inhibitors

            6.3.3.3. Others (Proteasome Inhibitors)

        6.3.4. Vaccines

            6.3.4.1. Preventive Vaccines

            6.3.4.2. Therapeutic Vaccines

        6.3.5. CAR-T Cells

        6.3.6. Angiogenesis Inhibitors

        6.3.7. Interleukins (IL)

        6.3.8. Others (Interferons (IFN), Gene Therapy, etc.)

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Cancer Biologics Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Application, 2017-2031

        7.3.1. Blood Cancer

        7.3.2. Lung Cancer

        7.3.3. Breast Cancer

        7.3.4. Colorectal Cancer

        7.3.5. Prostate Cancer

        7.3.6. Gastric Cancer

        7.3.7. Ovarian Cancer

        7.3.8. Others (Skin, Liver cancer, etc.)

    7.4. Market Attractiveness Analysis, by Application

8. Global Cancer Biologics Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by End-user, 2017-2031

        8.3.1. Hospitals

        8.3.2. Cancer Centers

        8.3.3. Academics & Research Institutes

    8.4. Market Attractiveness Analysis, by End-user

9. Global Cancer Biologics Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Cancer Biologics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017-2031

        10.2.1. Monoclonal Antibodies (mAb)

            10.2.1.1. Naked mAb

            10.2.1.2. Conjugated mAb

            10.2.1.3. Bispecific mAb

        10.2.2. Recombinants Proteins

        10.2.3. Cancer Growth Inhibitors

            10.2.3.1. Tyrosine Kinase Inhibitors

            10.2.3.2. mTOR Inhibitors

            10.2.3.3. Others (Proteasome Inhibitors)

        10.2.4. Vaccines

            10.2.4.1. Preventive Vaccines

            10.2.4.2. Therapeutic Vaccines

        10.2.5. CAR-T Cells

        10.2.6. Angiogenesis Inhibitors

        10.2.7. Interleukins (IL)

        10.2.8. Others (Interferons (IFN), Gene Therapy, etc.)

    10.3. Market Value Forecast, by Application, 2017-2031

        10.3.1. Blood Cancer

        10.3.2. Lung Cancer

        10.3.3. Breast Cancer

        10.3.4. Colorectal Cancer

        10.3.5. Prostate Cancer

        10.3.6. Gastric Cancer

        10.3.7. Ovarian Cancer

        10.3.8. Others (Skin, Liver cancer, etc.)

    10.4. Market Value Forecast, by End-user, 2017-2031

        10.4.1. Hospitals

        10.4.2. Cancer Centers

        10.4.3. Academics& Research Institutes

    10.5. Market Value Forecast, by Country, 2017-2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Application

        10.6.3. By End-user

        10.6.4. By Country

11. Europe Cancer Biologics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017-2031

        11.2.1. Monoclonal Antibodies (mAb)

            11.2.1.1. Naked mAb

            11.2.1.2. Conjugated mAb

            11.2.1.3. Bispecific mAb

        11.2.2. Recombinants Proteins

        11.2.3. Cancer Growth Inhibitors

            11.2.3.1. Tyrosine Kinase Inhibitors

            11.2.3.2. mTOR Inhibitors

            11.2.3.3. Others (Proteasome Inhibitors)

        11.2.4. Vaccines

            11.2.4.1. Preventive Vaccines

            11.2.4.2. Therapeutic Vaccines

        11.2.5. CAR-T Cells

        11.2.6. Angiogenesis Inhibitors

        11.2.7. Interleukins (IL)

        11.2.8. Others (Interferons (IFN), Gene Therapy, etc.)

    11.3. Market Value Forecast, by Application, 2017-2031

        11.3.1. Blood Cancer

        11.3.2. Lung Cancer

        11.3.3. Breast Cancer

        11.3.4. Colorectal Cancer

        11.3.5. Prostate Cancer

        11.3.6. Gastric Cancer

        11.3.7. Ovarian Cancer

        11.3.8. Others (Skin, Liver cancer, etc.)

    11.4. Market Value Forecast, by End-user, 2017-2031

        11.4.1. Hospitals

        11.4.2. Cancer Centers

        11.4.3. Academics& Research Institutes

    11.5. Market Value Forecast, by Country/Sub-region, 2017-2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Application

        11.6.3. By End-user

        11.6.4. By Country/Sub-region

12. Asia Pacific Cancer Biologics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017-2031

        12.2.1. Monoclonal Antibodies (mAb)

            12.2.1.1. Naked mAb

            12.2.1.2. Conjugated mAb

            12.2.1.3. Bispecific mAb

        12.2.2. Recombinants Proteins

        12.2.3. Cancer Growth Inhibitors

            12.2.3.1. Tyrosine Kinase Inhibitors

            12.2.3.2. mTOR Inhibitors

            12.2.3.3. Others (Proteasome Inhibitors)

        12.2.4. Vaccines

            12.2.4.1. Preventive Vaccines

            12.2.4.2. Therapeutic Vaccines

        12.2.5. CAR-T Cells

        12.2.6. Angiogenesis Inhibitors

        12.2.7. Interleukins (IL)

        12.2.8. Others (Interferons (IFN), Gene Therapy, etc.)

    12.3. Market Value Forecast, by Application, 2017-2031

        12.3.1. Blood Cancer

        12.3.2. Lung Cancer

        12.3.3. Breast Cancer

        12.3.4. Colorectal Cancer

        12.3.5. Prostate Cancer

        12.3.6. Gastric Cancer

        12.3.7. Ovarian Cancer

        12.3.8. Others (Skin, Liver cancer, etc.)

    12.4. Market Value Forecast, by End-user, 2017-2031

        12.4.1. Hospitals

        12.4.2. Cancer Centers

        12.4.3. Academics& Research Institutes

    12.5. Market Value Forecast, by Country, 2017-2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Application

        12.6.3. By End-user

        12.6.4. By Country/Sub-region

13. Latin America Cancer Biologics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017-2031

        13.2.1. Monoclonal Antibodies (mAb)

            13.2.1.1. Naked mAb

            13.2.1.2. Conjugated mAb

            13.2.1.3. Bispecific mAb

        13.2.2. Recombinants Proteins

        13.2.3. Cancer Growth Inhibitors

            13.2.3.1. Tyrosine Kinase Inhibitors

            13.2.3.2. mTOR Inhibitors

            13.2.3.3. Others (Proteasome Inhibitors)

        13.2.4. Vaccines

            13.2.4.1. Preventive Vaccines

            13.2.4.2. Therapeutic Vaccines

        13.2.5. CAR-T Cells

        13.2.6. Angiogenesis Inhibitors

        13.2.7. Interleukins (IL)

        13.2.8. Others (Interferons (IFN), Gene Therapy, etc.)

    13.3. Market Value Forecast, by Application, 2017-2031

        13.3.1. Blood Cancer

        13.3.2. Lung Cancer

        13.3.3. Breast Cancer

        13.3.4. Colorectal Cancer

        13.3.5. Prostate Cancer

        13.3.6. Gastric Cancer

        13.3.7. Ovarian Cancer

        13.3.8. Others (Skin, Liver cancer, etc.)

    13.4. Market Value Forecast, by End-user, 2017-2031

        13.4.1. Hospitals

        13.4.2. Cancer Centers

        13.4.3. Academics& Research Institutes

    13.5. Market Value Forecast, by Country/Sub-region, 2017-2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Application

        13.6.3. By End-user

        13.6.4. By Country/Sub-region

14. Middle East & Africa Cancer Biologics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017-2031

        14.2.1. Monoclonal Antibodies (mAb)

            14.2.1.1. Naked mAb

            14.2.1.2. Conjugated mAb

            14.2.1.3. Bispecific mAb

        14.2.2. Recombinants Proteins

        14.2.3. Cancer Growth Inhibitors

            14.2.3.1. Tyrosine Kinase Inhibitors

            14.2.3.2. mTOR Inhibitors

            14.2.3.3. Others (Proteasome Inhibitors)

        14.2.4. Vaccines

            14.2.4.1. Preventive Vaccines

            14.2.4.2. Therapeutic Vaccines

        14.2.5. CAR-T Cells

        14.2.6. Angiogenesis Inhibitors

        14.2.7. Interleukins (IL)

        14.2.8. Others (Interferons (IFN), Gene Therapy, etc.)

    14.3. Market Value Forecast, by Application, 2017-2031

        14.3.1. Blood Cancer

        14.3.2. Lung Cancer

        14.3.3. Breast Cancer

        14.3.4. Colorectal Cancer

        14.3.5. Prostate Cancer

        14.3.6. Gastric Cancer

        14.3.7. Ovarian Cancer

        14.3.8. Others (Skin, Liver cancer, etc.)

    14.4. Market Value Forecast, by End-user, 2017-2031

        14.4.1. Hospitals

        14.4.2. Cancer Centers

        14.4.3. Academics& Research Institutes

    14.5. Market Value Forecast, by Country/Sub-region, 2017-2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Drug Class

        14.6.2. By Application

        14.6.3. By End-user

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2021

    15.3. Company Profiles

        15.3.1. F. Hoffmann-La Roche Ltd.

            15.3.1.1. Company Overview

            15.3.1.2. Financial Overview

            15.3.1.3. Product Portfolio

            15.3.1.4. Business Strategies

            15.3.1.5. Recent Developments

        15.3.2. Amgen, Inc.

            15.3.2.1. Company Overview

            15.3.2.2. Financial Overview

            15.3.2.3. Product Portfolio

            15.3.2.4. Business Strategies

            15.3.2.5. Recent Developments

        15.3.3. Pfizer, Inc.

            15.3.3.1. Company Overview

            15.3.3.2. Financial Overview

            15.3.3.3. Product Portfolio

            15.3.3.4. Business Strategies

            15.3.3.5. Recent Developments

        15.3.4. GSK plc

            15.3.4.1. Company Overview

            15.3.4.2. Financial Overview

            15.3.4.3. Product Portfolio

            15.3.4.4. Business Strategies

            15.3.4.5. Recent Developments

        15.3.5. Bristol-Myers Squibb Company

            15.3.5.1. Company Overview

            15.3.5.2. Financial Overview

            15.3.5.3. Product Portfolio

            15.3.5.4. Business Strategies

            15.3.5.5. Recent Developments

        15.3.6. Abbott

            15.3.6.1. Company Overview

            15.3.6.2. Financial Overview

            15.3.6.3. Product Portfolio

            15.3.6.4. Business Strategies

            15.3.6.5. Recent Developments

        15.3.7. AstraZeneca

            15.3.7.1. Company Overview

            15.3.7.2. Financial Overview

            15.3.7.3. Product Portfolio

            15.3.7.4. Business Strategies

            15.3.7.5. Recent Developments

        15.3.8. Eli Lilly and Company

            15.3.8.1. Company Overview

            15.3.8.2. Financial Overview

            15.3.8.3. Product Portfolio

            15.3.8.4. Business Strategies

            15.3.8.5. Recent Developments

        15.3.9. Gilead Sciences, Inc.

            15.3.9.1. Company Overview

            15.3.9.2. Financial Overview

            15.3.9.3. Product Portfolio

            15.3.9.4. Business Strategies

            15.3.9.5. Recent Developments

        15.3.10. Johnson & Johnson Services, Inc.

            15.3.10.1. Company Overview

            15.3.10.2. Financial Overview

            15.3.10.3. Product Portfolio

            15.3.10.4. Business Strategies

            15.3.10.5. Recent Developments

List of Tables

Table 01: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 02: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031

Table 03: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031

Table 04: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031

Table 05: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031

Table 06: Global Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031

Table 07: Global Cancer Biologics Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 08: North America Cancer Biologics Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 09: North America Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 10: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031

Table 11: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031

Table 12: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031

Table 13: North America Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031

Table 14: North America Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031

Table 15: Europe Cancer Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 16: Europe Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 17: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031

Table 18: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031

Table 19: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031

Table 20: Europe Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031

Table 21: Europe Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031

Table 22: Asia Pacific Cancer Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 23: Asia Pacific Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 24: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031

Table 25: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031

Table 26: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031

Table 27: Asia Pacific Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031

Table 28: Asia Pacific Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031

Table 29: Latin America Cancer Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 30: Latin America Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 31: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031

Table 32: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031

Table 33: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031

Table 34: Latin America Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031

Table 35: Latin America Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031

Table 36: Middle East and Africa Cancer Biologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 37: Middle East and Africa Cancer Biologics Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 38: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Monoclonal Antibodies (mAb), 2017-2031

Table 39: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Cancer Growth Inhibitors, 2017-2031

Table 40: Global Cancer Biologics Market Size (US$ Mn) Forecast, by Vaccines, 2017-2031

Table 41: Middle East and Africa Cancer Biologics Market Size (US$ Mn) Forecast, by Application, 2017-2031

Table 42: Middle East and Africa Cancer Biologics Market Size (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

Figure 01: Global Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031

Figure 02: Global Cancer Biologics Market Value Share, by Drug Class, 2022

Figure 03: Global Cancer Biologics Market Value Share, by Application, 2022

Figure 04: Global Cancer Biologics Market Value Share, by End-user, 2022

Figure 05: Global Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 06: Global Cancer Biologics Market Revenue (US$ Mn), by Monoclonal Antibodies (mAb), 2017-2031

Figure 07: Global Cancer Biologics Market Revenue (US$ Mn), by Recombinants Proteins, 2017-2031

Figure 08: Global Cancer Biologics Market Revenue (US$ Mn), by Cancer Growth Inhibitors, 2017-2031

Figure 09: Global Cancer Biologics Market Revenue (US$ Mn), by Vaccines, 2017-2031

Figure 10: Global Cancer Biologics Market Revenue (US$ Mn), by CAR-T Cells, 2017-2031

Figure 11: Global Cancer Biologics Market Revenue (US$ Mn), by Angiogenesis Inhibitors, 2017-2031

Figure 12: Global Cancer Biologics Market Revenue (US$ Mn), by Interleukins (IL), 2017-2031

Figure 13: Global Cancer Biologics Market Revenue (US$ Mn), by Others, 2017-2031

Figure 14: Global Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031

Figure 15: Global Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031

Figure 16: Global Cancer Biologics Market Revenue (US$ Mn), by Blood Cancer, 2017-2031

Figure 17: Global Cancer Biologics Market Revenue (US$ Mn), by Lung Cancer, 2017-2031

Figure 18: Global Cancer Biologics Market Revenue (US$ Mn), by Breast Cancer, 2017-2031

Figure 19: Global Cancer Biologics Market Revenue (US$ Mn), by Colorectal Cancer, 2017-2031

Figure 20: Global Cancer Biologics Market Revenue (US$ Mn), by Prostate Cancer, 2017-2031

Figure 21: Global Cancer Biologics Market Revenue (US$ Mn), by Gastric Cancer, 2017-2031

Figure 22: Global Cancer Biologics Market Revenue (US$ Mn), by Ovarian Cancer, 2017-2031

Figure 23: Global Cancer Biologics Market Revenue (US$ Mn), by Other Cancer, 2017-2031

Figure 24: Global Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031

Figure 25: Global Cancer Biologics Market Value Share Analysis, by Region, 2022 and 2031

Figure 26: Global Cancer Biologics Market Attractiveness Analysis, by Region, 2023-2031

Figure 27: North America Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031

Figure 28: North America Cancer Biologics Market Value Share Analysis, by Country, 2022 and 2031

Figure 29: North America Cancer Biologics Market Attractiveness Analysis, by Country, 2023-2031

Figure 30: North America Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 31: North America Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031

Figure 32: North America Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031

Figure 33: North America Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031

Figure 34: North America Cancer Biologics Market Value Share Analysis, by End-user, 2022 and 2031

Figure 35: North America Cancer Biologics Market Attractiveness Analysis, by End-user, 2023-2031

Figure 36: Europe Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031

Figure 37: Europe Cancer Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 38: Europe Cancer Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 39: Europe Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 40: Europe Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031

Figure 41: Europe Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031

Figure 42: Europe Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031

Figure 43: Europe Cancer Biologics Market Value Share Analysis, by End-user, 2022 and 2031

Figure 44: Europe Cancer Biologics Market Attractiveness Analysis, by End-user, 2023-2031

Figure 45: Asia Pacific Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031

Figure 46: Asia Pacific Cancer Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 47: Asia Pacific Cancer Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 48: Asia Pacific Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 49: Asia Pacific Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031

Figure 50: Asia Pacific Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031

Figure 51: Asia Pacific Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031

Figure 52: Asia Pacific Cancer Biologics Market Value Share Analysis, by End-user, 2022 and 2031

Figure 53: Asia Pacific Cancer Biologics Market Attractiveness Analysis, by End-user, 2023-2031

Figure 54: Latin America Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031

Figure 55: Latin America Cancer Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 56: Latin America Cancer Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 57: Latin America Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 58: Latin America Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031

Figure 59: Latin America Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031

Figure 60: Latin America Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031

Figure 61: Latin America Cancer Biologics Market Value Share Analysis, by End-user, 2022 and 2031

Figure 62: Latin America Cancer Biologics Market Attractiveness Analysis, by End-user, 2023-2031

Figure 63: Middle East and Africa Cancer Biologics Market Value (US$ Mn) Forecast, 2017-2031

Figure 64: Middle East and Africa Cancer Biologics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 65: Middle East and Africa Cancer Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 66: Middle East and Africa Cancer Biologics Market Value Share Analysis, by Drug Class, 2022 and 2031

Figure 67: Middle East and Africa Cancer Biologics Market Attractiveness Analysis, by Drug Class, 2023-2031

Figure 68: Middle East and Africa Cancer Biologics Market Value Share Analysis, by Application, 2022 and 2031

Figure 69: Middle East and Africa Cancer Biologics Market Attractiveness Analysis, by Application, 2023-2031

Figure 70: Middle East and Africa Cancer Biologics Market Value Share Analysis, by End-user, 2022 and 2031

Figure 71: Middle East and Africa Cancer Biologics Market Attractiveness Analysis, by End-user, 2023-2031

Copyright © Transparency Market Research, Inc. All Rights reserved